[144] Mural Oncology plc SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) – Form 144

An affiliate has filed a Form 144 to sell up to 11,914 common shares through Morgan Stanley Smith Barney on or about 07/09/2025. The shares have an aggregate market value of $452,631.92 and represent roughly 0.02 % of the company’s 57,915,199 shares outstanding, indicating a very limited effect on the public float.

The seller acquired the shares on the same date via a cash-settled stock-option exercise. In the prior three months the same individual sold 7,000 shares (4,091 on 07/01/2025 and 2,909 on 06/24/2025) for total gross proceeds of $237,341.32.

The filing states that the insider is unaware of any undisclosed material adverse information and is complying with Rule 144 sale restrictions. Given the modest share count involved, the proposed disposition appears to be a routine liquidity move with minimal expected market impact.

Positive

• None.

Negative

• Insider share sale: Even though small, planned disposition could be viewed as a modest bearish signal by some investors.

Insights

Financial Analyst

TL;DR: Insider plans to sell 11.9k AGIO shares (0.02 % float); impact likely neutral.

The Form 144 reveals a small, pre-announced insider sale under Rule 144. The transaction’s dollar value (~$0.45 million) and percentage of outstanding shares are immaterial for a company with nearly 58 million shares. Prior recent sales total only 7,000 shares, further underscoring the low volume. Because the filing explicitly affirms no undisclosed adverse information and follows standard compliance procedures, I view the disclosure as neutral. It neither signals operational weakness nor materially alters insider ownership. Short-term price pressure should be negligible due to the modest size relative to average daily trading volume.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	MorganStanley Private Bank Harborside 2 200 Hudson Street, Suite 501 Jersey City NJ 07311	12513	30469	17268881	07/07/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	07/05/2025	Restricted Stock Units	Issuer			12513	07/05/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AGIO shares are being offered for sale under this Form 144?

The insider intends to sell 11,914 common shares of Agios Pharmaceuticals.

What is the estimated value of the AGIO shares to be sold?

The aggregate market value is listed as $452,631.92.

What percentage of Agios Pharmaceuticals’ outstanding shares does the sale represent?

The sale equals roughly 0.02 % of the 57,915,199 shares outstanding.

When is the approximate sale date for the AGIO shares?

The filing lists an approximate sale date of 07/09/2025 on the NASDAQ.

Has the insider sold AGIO shares recently?

Yes. In the last three months the insider sold 4,091 shares on 07/01/2025 and 2,909 shares on 06/24/2025.

What was the method of acquiring the shares now being sold?

The shares were acquired on 07/09/2025 through a stock-option exercise paid in cash.